Sangamo Therapeutics, INC: insider trades · United States · SEC (Form 4)

About Sangamo Therapeutics, INC

Sangamo Therapeutics, Inc. is a U.S.-based genomic medicine company focused on gene therapy, genome engineering, gene regulation, and selected cell-therapy applications. The company is listed in the United States, having traded on Nasdaq under the ticker SGMO and later transitioning to the OTCQB Venture Market in May 2026 after a Nasdaq delisting process. Its headquarters are in Richmond, California, United States. Founded in 1995 by Edward Lanphier, Sangamo built its scientific identity around proprietary zinc finger technology. Over time, that platform expanded into zinc finger nucleases, gene regulation, in vivo genome editing, and epigenetic modulation. The company positions itself as one of the few developers spanning multiple layers of genomic medicine, aiming to address severe diseases where current standards of care are limited largely to symptom management rather than durable disease modification. For investors, Sangamo is best understood as a clinical-stage biotech with a long scientific track record but no broad commercial franchise. Its pipeline is concentrated in a small number of high-value, high-risk programs. The lead asset is isaralgagene civaparvovec, also known as ST-920, a one-time gene therapy candidate for Fabry disease. In 2025 and 2026, Sangamo reported positive registrational study data and said it was advancing a rolling BLA submission to the FDA under an accelerated approval pathway. The company also highlighted continuing work in neurology, including programs in chronic neuropathic pain and prion disease, as well as presentations on zinc finger epigenetic regulation and modular integrase technologies. This pipeline mix shows Sangamo’s emphasis on rare, severe indications with meaningful unmet medical need. Sangamo’s business model combines wholly owned assets with partnerships. Historically, the company has worked with major pharmaceutical companies, which has helped validate its platform and diversify funding sources. Its competitive position depends on whether its proprietary genome-engineering know-how can continue to translate into clinically meaningful results, regulatory acceptance, and eventually commercialization. In a crowded field that includes CRISPR-based developers and other gene-therapy players, Sangamo’s differentiation lies in its longstanding zinc finger expertise and its broader genomic medicine toolkit. Recent corporate highlights include Fabry disease regulatory progress, new pipeline presentations at the 2026 ASGCT annual meeting, and the significant negative event of losing its Nasdaq listing and moving to OTCQB in May 2026. That market change is important for investors because it typically signals weaker liquidity and higher financing risk. Overall, Sangamo remains a highly speculative biotechnology name: scientifically interesting, clinically focused, but still dependent on execution, regulatory milestones, and additional capital to fund operations.